The Carl June Lab has once again advanced the frontiers of immunotherapy research with their recently published study, “Stem Loop Mediated Transgene Modulation in Human T Cells” featured in ACS Synthetic Biology. This work unveils an innovative approach to regulating transgene expression in primary human T cells using engineered RNA stem loops. By leveraging the endogenous regulatory mechanisms of proteins like Regnase-1 and Roquin-1, the team has achieved dynamic, stimulation-dependent control of transgenes in engineered T cells, including CAR-T cells.
This development marks an exciting step forward in enhancing the precision and safety of CAR-T therapies. It demonstrates how cell-autonomous control systems can minimize reliance on external molecular inputs, a shift that could reshape therapeutic approaches in oncology and beyond.
We are proud to highlight that Cytoart’s FMC63-PE antibody (R19M) played a key role in this research, enabling precise characterization and analysis of CAR-positive cells through advanced flow cytometry. Our mission has always been to empower cutting-edge research with high-quality tools, and we are thrilled to see our products supporting discoveries with real-world impact.
The potential applications of this study are vast, ranging from reducing toxicity in CAR-T treatments to enabling more sophisticated genetic circuits in cell therapy. As the field progresses, we remain committed to providing innovative solutions to researchers worldwide.
Congratulations again to the June Lab for this remarkable achievement. We are excited to see how these findings will inspire the next generation of cellular therapies.
To explore how Cytoart’s antibodies can enhance your research, contact us today!
#Immunotherapy #CAR_TResearch #TCellEngineering #SyntheticBiology #CancerResearch #Bioswan #Cytoart #ScientificInnovation #FlowCytometry #Biotechnology #CellTherapy
